Table 3.
Patient characteristics of subjects receiving alternate-day gefitinib therapy following liver damage
| Age (years) |
Sex | Alcohol consumption | Hepatitis virus | Previous chemotherapy | Type of EGFR mutation | Days from initiating gefitinib treatment to cessation | Cessation (days) |
Response rate |
|---|---|---|---|---|---|---|---|---|
| 64 | F | Nondrinker | None | − | Exon 19 deletion | 35 | 13 | CR |
| 64 | F | Nondrinker | None | + | Exon 21 L858R | 36 | 7 | PR |
| 81 | F | Nondrinker | Unknown | − | Exon 19 deletion | 39 | 14 | PD |
| 88 | M | Nondrinker | None | + | Exon 21 L858R | 92 | 19 | SD |
| 62 | F | Nondrinker | None | + | Exon 21 L858R | 105 | 10 | SD |
| 62 | F | 30.8 g/day | None | + | Unknown | 118 | 14 | PR |
| 80 | M | Nondrinker | None | + | Exon 21 L858R | 341 | 22 | PR |
| 70 | F | Nondrinker | HCV | + | Exon 18 G719X | 355 | 10 | PR |
| 60 | F | Nondrinker | None | + | Exon 19 deletion | 386 | 7 | PR |
Abbreviations: EGFR, epidermal growth-factor receptor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HCV, hepatitis C virus.